KRAS and colorectal carcinoma: Because the mutations in KRAS codon 13 represent a high proportion of the population suffering from CRC, the issue regarding the possible response of this mutated form of KRAS to anti-EGFR therapies should be considered relevant from biological, ethical and economical perspectives.